Results 181 to 190 of about 74,157 (302)

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Efficacy of Janus kinase inhibitors in the treatment of acute exacerbations of rheumatoid arthritis-associated interstitial lung disease: a retrospective observational case series. [PDF]

Front Immunol
Okamoto M, Fujikawa K, Mihara T, Doi S, Tomari S, Koga T, Kido T, Sakamoto N, Mizokami A, Mukae H, Kawakami A.   +10 more
europepmc   +1 more source

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In a real‐world cohort of patients with highly refractory perianal Crohn's disease, upadacitinib induced clinical remission at 12 months in 26% of patients with fistulizing disease and 25% of those with isolated anal ulcerations. ABSTRACT Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD ...
Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne‐Laure Pelletier, Mathieu Uzzan, Aurélien Amiot, Morgane Amil, Lucine Vuitton, Mathurin Fumery, Anne Bozon   +13 more
wiley   +1 more source

Janus kinase inhibitors: another potential for uveitis treatment? [PDF]

Ann Eye Sci
Emami S, Kaisari E, Janetos TM.
europepmc   +1 more source

FDA-approved small-molecule kinase inhibitors [PDF]

, 2015
Clausen, Mads Hartvig, Nielsen, Thomas E., Wu, Peng   +2 more
core   +1 more source

Integrated proteomic and metabolomic profiling reveals sex‐stratified biomarkers predicting chronicity in paediatric primary immune thrombocytopenia

British Journal of Haematology, EarlyView.
Construction of the immune thrombocytopenia (ITP) chronicity prediction model was based on sex‐stratified multi‐omics analysis, identifying key sex‐specific predictors (intercellular adhesion molecule‐1 [ICAM‐1] and biopterin in males; actin, alpha 2, smooth muscle, aorta [ACTA‐2] and N6‐acetyl‐L‐lysine in females).
Yuanyuan Xue, Rongrong Zhang, Dongmei Liang, Yupeng Xu, Zhaofang Tian, Xiaohong Dai, Wei Xu, Qingqing Cao, Haiyan Zhu, Yun Wang, Yufang Yuan   +10 more
wiley   +1 more source

Association of Venous Thromboembolism Risk with Atopic Dermatitis and Janus Kinase Inhibitors Treatment: A Mendelian Randomization Study. [PDF]

Clin Appl Thromb Hemost
Chen Z, Wang S, Wang Y.
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis. [PDF]

Arthritis Res Ther
Nozaki Y, Kishimoto K, Itami T, Tomita D, Wada Y, Kotani T, Takeuchi T, Hidaka T, Hino S, Miyamoto T, Miyake H, Hatta K, Mamoto K, Yamada Y, Okano T, Okano T, Saegusa J, Horita M, Nishida K, Kinoshita K, Rai S.   +20 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source